Compliance with good manufacturing practice (“GMP”) is mandatory for all medicinal products that have been granted a marketing authorisation. Likewise, the manufacture of investigational medicinal products must be in accordance with GMP. Advanced therapy medicinal products that are administered to patients under Article 3(7) of Directive 2001/83/EC1 (so called “hospital exemption”) must be manufactured under equivalente quality standards to the manufacturing of advanced therapy medicinal products with a marketing authorisation.
News & Trends
Procurar
Recentes
- Team-NB Position Paper: MDR Certification Process (including Pre-application, Application and Post Application phases) – Consensus document
- 2025 AI Observatory report
- The EU new standard template covering recruitment and informed consent procedures.
- EXTENSION OF THE MDR TRANSITIONAL PERIOD AND REMOVAL OF THE ‘SELL OFF’ PERIODS – Q&A on practical aspects related to the implementation of Regulation (EU) 2023/607
- MEDTECH EUROPE : An Improved Regulatory Framework: What Do Europe’s Diagnostics Need?
- European Data Protection Board public consultation on the draft Guidelines on the processing of personal data for scientific research
- Statistical Approaches to Establishing Bioequivalence
- Modelo de reporte trimestral de atividades de cultivo e fabrico de canábis para fins medicinais

